Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid... see more

TSXV:MIR - Post Discussion

MedMira Inc > Copy and pasted from Yahoo Finance. Interesting.
View:
Post by conservative2 on Dec 02, 2021 5:48pm

Copy and pasted from Yahoo Finance. Interesting.

MedMira will provide a regulatory and corporate update on the 22nd of December 2021, in the event of any material
changes, these will be provided before that date. In addition, the Company further enhanced its technology by developing a new production process for its colloidal gold immuno-conjugates. This will be launched in the coming months and further enhances the ease-of-use and with it provides additional benefits to the end-users. Subsequent to the financial year end 2021, MedMira has successfully completed its latest FDA inspection of the Company’s biological medical device products.In addition, the Company announces that it has completed the MDSAP audit and shall receive the MDSAP certification in early December 2021. Furthermore, the Company received the registered trademark for its REVEALCOVID-19®. The Company’s Finance team continued its fiscal constraints to maintain its low fixed costs with the aim to achieve breakeven and subsequent profitability within a short period of time. During FY2021, the Company continued its efforts to renegotiate its debt and achieved a forbearance agreement with MedMira’s largest debt holder which allows the Company to defer principal and interest payments for 12 months. This may be extended further depending on the growth of the Company. Subsequent to the financial year end 2021, MedMira entered into a financial package agreement pending on regulatory approval which will provide the Company with additional cash to execute its clinical trials (G4 HIV CLIA-waived Rapid Test), to continue its operations and to further invest into the manufacturing facility in Halifax. As an additional part of this agreement, MedMira and its stakeholders will benefit from a significant debt reduction to further support the Company’s going concern.
Comment by EtheGreat on Dec 02, 2021 7:30pm
"...shall receive MDSAP Certification in early December 2021" & "completed its latest FDA inspection of Company's biological medical device products." -- GREAT-HEAVENS-To-MEGATRONS !!! -- "conservative2" Great Find & Thanks a Zillion ! -- i see FOMO Tsunami return to $.50cent USD immediately !!! -- EtheGreat or Not ?
Comment by conservative2 on Dec 02, 2021 7:57pm
For sure. Hold on for the ride.  When it happens it will be VERY FAST!! Increments of information will be forthcoming, each of which will cause Medmira stock value to explode.  One error in your descriptor though.  IF you date back to Bugs Bunny time, you would know the saying would be, "Heavens to Mergetroid!"  with plenty of spit being shot from the cartoon ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities